Evidence Explorer / Collection
FOLLOW THE CITATION
Studies, guidelines & source documents
394 distinct source links across the 109 published records. This is a reference index, not a count of clinical trials: it includes papers, guidelines, patient resources, trial listings and product information.
References from existing reviews are indexed here alongside the 76 dedicated evidence briefs. Inclusion does not mean every older citation has been freshly reappraised. Check the original publication, date, corrections and the limits discussed in the linked record.
Core research and clinical resources
- NCI PDQ integrative therapies summaries
- NCCIH: complementary approaches in cancer
- SIO–ASCO pain guideline
- ASCO–SIO fatigue guideline
- SIO–ASCO anxiety and depression guideline
- ASCO cannabis and cannabinoid guideline
References by evidence record
Acetyl-L-carnitine for taxane neuropathy — 2 linked sources
Read the interpretation and limitations →
Evidence basis: Randomized double-blind trial; 409 evaluable participants
- Hershman et al., 2013 randomized trial (PMID 23733756)
- SWOG S0715 two-year follow-up (PMID 29361042)
Acupuncture for aromatase-inhibitor joint pain — 4 linked sources
Read the interpretation and limitations →
Evidence basis: SWOG S1200 randomized trial, 52-week follow-up and SIO–ASCO guideline
- SWOG S1200 six-week randomized trial (PMID 29998338)
- SWOG S1200 52-week follow-up (PMID 36367721)
- SIO–ASCO integrative pain guideline, 2022 (PMID 36122322)
- NCCIH acupuncture safety overview
Acupuncture for dry mouth — 3 linked sources
Read the interpretation and limitations →
Evidence basis: Multicenter randomized trial, 258 participants
- multicenter randomized trial (jamanetwork.com)
- 2019 randomized trial (jamanetwork.com)
- MASCC/ISOO/ASCO guideline (mascc.memberclicks.net)
Alpha-lipoic acid for chemotherapy neuropathy — 31 linked sources
Read the interpretation and limitations →
Evidence basis: Randomized trial plus broader narrative review
- SYDNEY 2 (PMID 17065669)
- 2024 Cochrane review (PMID 38205823)
- NATHAN 1 trial (PMID 21775755)
- 2026 OPTIMUM trial (dom-pubs.onlinelibrary.wiley.com)
- 2026 network meta-analysis (www.frontiersin.org)
- 2014 placebo-controlled prevention trial (PMID 24362907)
- 2022 breast cancer trial (link.springer.com)
- Studies combining ALA with ipidacrine (PMID 41058457)
- rare cases of autoimmune hypoglycemia have been reported (PMID 30086435)
- placebo-controlled study of 409 evaluable women (PMID 23733756)
- small randomized omega-3 trial (PMID 22894640)
- 86-person randomized glutamine study (PMID 17405895)
- larger phase 3 trial with 189 evaluable patients (PMID 20936417)
- placebo-controlled B-complex trial (PMID 27612466)
- one-year trial in 90 metformin-treated people with diabetes and low B12 levels (PMID 33513879)
- excess supplemental B6 can itself cause sensory neuropathy (ods.od.nih.gov)
- 2026 curcumin trial (link.springer.com)
- 2025 trial in children with acute lymphoblastic leukemia (PMID 40000988)
- 2024 report (PMID 39494844)
- 2025 paclitaxel study (PMID 40661819)
- phase 3 N08CA trial (PMID 24619793)
- GENIUS phase 3 oxaliplatin trial (PMID 25627820)
- later small paclitaxel trial (PMID 39256982)
- 2025 CBD/THC trial (www.frontiersin.org)
- topical CBD pilot (pmc.ncbi.nlm.nih.gov)
- 8% capsaicin patch (PMID 31308732)
- 2024 STOP trial (jamanetwork.com)
- A small randomized acupuncture trial (jamanetwork.com)
- Cooling and compression trials during taxane infusions (pmc.ncbi.nlm.nih.gov)
- 2020 ASCO guideline (PMID 32663120)
- a study of ALA, Tai Chi/Qi Gong and acupuncture in colorectal cancer survivors (www.cancer.gov)
American ginseng for fatigue — 2 linked sources
Read the interpretation and limitations →
Evidence basis: N07C2 placebo-controlled trial; ASCO–SIO guideline
- N07C2 randomized, double-blind trial (PMID 23853057)
- 2024 ASCO–Society for Integrative Oncology fatigue guideline (PMID 38754041)
Cannabinoids for cancer pain — 5 linked sources
Read the interpretation and limitations →
Evidence basis: Nabiximols randomized trials, including phase III
- randomized graded-dose trial (PMID 22483680)
- phase 3 trial (PMID 28923526)
- phase 3 studies (PMID 28785408)
- MASCC guideline (PMID 36872397)
- ASCO guideline (PMID 38478773)
Cannabinoids for refractory chemotherapy nausea — 1 linked sources
Read the interpretation and limitations →
Evidence basis: ASCO cannabis and cannabinoid guideline, 2024
- ASCO cannabis and cannabinoids guideline, 2024 (PMID 38478773)
CBT-I — 4 linked sources
Read the interpretation and limitations →
Evidence basis: Randomized trials and ESMO insomnia guidance
- 2023 ESMO insomnia guideline (PMID 38158225)
- 2018 trial (PMID 29471478)
- full trial report (pmc.ncbi.nlm.nih.gov)
- systematic review published August 31, 2026 (doi.org)
Colorectal surgery prehabilitation — 3 linked sources
Read the interpretation and limitations →
Evidence basis: PREHAB randomized trial, 251 participants
- PREHAB randomized trial (PMID 36988937)
- 2024 systematic review (PMID 38914837)
- 2025 ERAS Society colorectal guideline (www.surgjournal.com)
Complementary nausea approaches — narrative overview
No external hyperlinks were present in this overview when indexed. Use the separately sourced intervention records before relying on a specific claim.
Cooling gloves & socks — 5 linked sources
Read the interpretation and limitations →
Evidence basis: Small randomized and self-controlled studies
- self-controlled study (PMID 29924336)
- randomized trial (doi.org)
- 2024 meta-analysis (PMID 38955817)
- CIPN guideline (PMID 32663120)
- phase III trial (clinicaltrials.gov)
Curcumin for radiation skin reactions — 5 linked sources
Read the interpretation and limitations →
Evidence basis: Large oral RCT; small topical studies
- multicenter randomized trial, published online in December 2017 and in the 2018 journal issue (link.springer.com)
- pilot placebo-controlled trial published March 27, 2025 (PMID 40145664)
- systematic review published September 14, 2026 (link.springer.com)
- NCCIH’s April 2025 safety summary (www.nccih.nih.gov)
- NCI’s curcumin summary (www.cancer.gov)
Exercise during ADT — 5 linked sources
Read the interpretation and limitations →
Evidence basis: Supervised aerobic and resistance exercise trials
- randomized trial (PMID 31605663)
- trial of 57 men (PMID 19949016)
- year-long study of 163 men (PMID 28249801)
- meta-analysis of 30 randomized trials (PMID 39766184)
- exercise guideline (PMID 35576506)
Exercise with metastatic breast cancer — 4 linked sources
Read the interpretation and limitations →
Evidence basis: PREFERABLE-EFFECT, 357 participants
- 2024 PREFERABLE-EFFECT randomized trial (www.nature.com)
- research program (www.dkfz.de)
- secondary analysis published April 13, 2026 (pmc.ncbi.nlm.nih.gov)
- International Bone Metastases Exercise Working Group (ascopubs.org)
Fasting around treatment — 9 linked sources
Read the interpretation and limitations →
Evidence basis: Small trials and conference reports
- 2026 ASCO Annual Meeting, abstract 5517 (ascopubs.org)
- research regimen permitted fluids and up to 350 calories daily (www.asco.org)
- ASCO reported (www.asco.org)
- January 2026 breast cancer report (PMID 41165048)
- 2025 systematic review (PMID 40970988)
- 2014 study of eight healthy men (pmc.ncbi.nlm.nih.gov)
- 2024 analysis of fasting-mimicking diet trials (pmc.ncbi.nlm.nih.gov)
- ESPEN’s 2021 cancer nutrition guidance (www.espen.org)
- Pregnancy, breastfeeding and an eating-disorder history (www.hopkinsmedicine.org)
Ginger for chemotherapy nausea — 2 linked sources
Read the interpretation and limitations →
Evidence basis: Randomized placebo-controlled trial
- randomized, double-blind trial published in 2012 (PMID 21818642)
- 2022 umbrella review of ginger and human health (PMID 35147170)
Handheld fan for breathlessness — 3 linked sources
Read the interpretation and limitations →
Evidence basis: Small randomized trial, 40 participants
- randomized trial of 40 patients (PMID 30009968)
- 2026 systematic review and meta-analysis (PMID 42174753)
- advanced-cancer dyspnea guideline (PMID 33617290)
Hydration and electrolytes — 9 linked sources
Read the interpretation and limitations →
Evidence basis: Clinical nutrition and supportive-care guidance
- More on when to seek care. (www.cancer.org)
- eviQ’s cisplatin guidance (www.eviq.org.au)
- VA patient guidance (www.nutrition.va.gov)
- overhydration (www.mdanderson.org)
- Oral rehydration research (pure.johnshopkins.edu)
- Memorial Sloan Kettering’s ileostomy guidance (www.mskcc.org)
- MD Anderson finds no evidence supporting these health claims. (www.mdanderson.org)
- fluid retention (www.mdanderson.org)
- NCI on hydration near the end of life (www.cancer.gov)
Hypnosis for procedural pain — 1 linked sources
Read the interpretation and limitations →
Evidence basis: SIO–ASCO integrative pain guideline
- SIO–ASCO integrative pain guideline, 2022 (PMID 36122322)
IV vitamin C in pancreatic cancer — 2 linked sources
Read the interpretation and limitations →
Evidence basis: Small randomized trial; 36 randomized, 34 treated
- 2024 randomized trial of pharmacological ascorbate (PMID 39369582)
- NCI: Intravenous Vitamin C (PDQ) (www.cancer.gov)
L-glutamine in pancreatic cancer — 2 linked sources
Read the interpretation and limitations →
Evidence basis: GlutaPanc single-arm phase I; 16 evaluable
- GlutaPanc phase 1 report, Nature Cancer (2026) (www.nature.com)
- Published study protocol (2023) (PMID 37239063)
Laetrile / amygdalin (“B17”) — 1 linked sources
Read the interpretation and limitations →
Evidence basis: NCI review, including a phase II study
- NCI: Laetrile/Amygdalin (PDQ) (www.cancer.gov)
Lung surgery prehabilitation — 3 linked sources
Read the interpretation and limitations →
Evidence basis: Multicenter randomized trial, 122 participants
- 2025 multicenter randomized trial (PMID 40374400)
- 2026 meta-analysis (PMID 40719350)
- review of six randomized trials (PMID 34417883)
Massage for palliative cancer pain — 1 linked sources
Read the interpretation and limitations →
Evidence basis: SIO–ASCO integrative pain guideline
- SIO–ASCO integrative pain guideline, 2022 (PMID 36122322)
Medicinal mushroom extracts — 2 linked sources
Read the interpretation and limitations →
Evidence basis: NCI evidence summary of clinical and preclinical studies
- NCI: Medicinal Mushrooms (PDQ) (www.cancer.gov)
- NCI listing: reishi for AI-related symptoms; check current status (www.cancer.gov)
Melatonin for sleep — 5 linked sources
Read the interpretation and limitations →
Evidence basis: Placebo-controlled trial, 95 participants
- 2014 placebo-controlled trial (pmc.ncbi.nlm.nih.gov)
- September 2026 report (PMID 42533530)
- April 30, 2025 Cochrane review (www.cochrane.org)
- 2023 ESMO guideline (pmc.ncbi.nlm.nih.gov)
- NCCIH notes (www.nccih.nih.gov)
Mindfulness for anxiety — 4 linked sources
Read the interpretation and limitations →
Evidence basis: Randomized trials and SIO–ASCO guidance
- 2012 randomized trial (PMID 22430268)
- 2023 Society for Integrative Oncology–ASCO guideline (PMID 37582238)
- ASCO anxiety and depression guideline (PMID 37075262)
- NCCIH notes (www.nccih.nih.gov)
Mistletoe extracts — 1 linked sources
Read the interpretation and limitations →
Evidence basis: Heterogeneous clinical studies summarized by NCI
- NCI: Mistletoe Extracts (PDQ) (www.cancer.gov)
Nutrition shakes — 19 linked sources
Read the interpretation and limitations →
Evidence basis: Nutrition guidance and product-label comparison
- NCI nutrition guidance (www.cancer.gov)
- Ensure Original (retail) (www.abbottnutrition.com)
- Ensure Plus (retail) (www.abbottnutrition.com)
- Ensure COMPLETE (www.ensure.com)
- BOOST Original (drink) (www.boost.com)
- BOOST Plus (www.boost.com)
- BOOST Very High Calorie (www.boost.com)
- BOOST Breeze (www.boost.com)
- Kate Farms Standard 1.0 (shop.katefarms.com)
- Kate Farms Standard 1.4 (shop.katefarms.com)
- Kate Farms Nutrition Shake (shop.katefarms.com)
- Kate Farms Peptide 1.5 (shop.katefarms.com)
- Orgain Vegan Organic Nutrition, Vanilla Bean (orgain.com)
- Compleat Standard 1.4 (www.compleat.com)
- MSK explains why cutting out sugar cannot starve cancer selectively. (www.mskcc.org)
- Open calorie counter + BMI calculator → (missing-script-nutrition-tools.sratrade.chatgpt.site)
- ESPEN’s general starting range of 25–30 kcal/kg/day (www.espen.org)
- BMI = weight in kilograms ÷ height in meters squared. (www.cdc.gov)
- NICE guidance on refeeding precautions. (www.nice.org.uk)
Omega-3s for weight loss — 6 linked sources
Read the interpretation and limitations →
Evidence basis: Large randomized trials; nutrition guidance
- multicenter randomized trial (PMID 16849754)
- phase III trial involving 421 people with incurable cancer and wasting (PMID 15197210)
- 2021 ESPEN nutrition guideline (www.espen.org)
- ASCO cachexia guideline (ascopubs.org)
- 2026 umbrella review (PMID 41950300)
- NIH Office of Dietary Supplements (ods.od.nih.gov)
Oral cryotherapy / ice chips — 4 linked sources
Read the interpretation and limitations →
Evidence basis: Randomized trials and MASCC/ISOO guidance
- Cochrane review (PMID 26695736)
- MASCC/ISOO guideline (mascc.memberclicks.net)
- prospective randomized study (PMID 16633359)
- 2020 systematic guideline review (PMID 31836937)
Oxybutynin for hot flashes — 4 linked sources
Read the interpretation and limitations →
Evidence basis: Placebo-controlled trial, 150 randomized
- 2019 ACCRU trial (pmc.ncbi.nlm.nih.gov)
- 2026 ASCO systematic-review abstract (ascopubs.org)
- 2023 Menopause Society position statement (PMID 37252752)
- prescribing information (dailymed.nlm.nih.gov)
Pelvic-floor training — 5 linked sources
Read the interpretation and limitations →
Evidence basis: Randomized trials
- randomized trial of 97 men (PMID 31729959)
- more recent randomized trial (PMID 38658057)
- MAPS trial (PMID 21741700)
- 2024 meta-analysis (PMID 39104234)
- AUA/GURS/SUFU guideline (www.auanet.org)
Peppermint aromatherapy for nausea — 1 linked sources
Read the interpretation and limitations →
Evidence basis: Open-label, quasi-randomized controlled pilot
- Peppermint-oil quasi-randomized pilot study (PMID 33197662)
Probiotics during pelvic radiation — 4 linked sources
Read the interpretation and limitations →
Evidence basis: Randomized placebo-controlled trials
- double-blind randomized trial (PMID 24200199)
- meta-analysis of randomized trials (PMID 28575095)
- Oncology Nursing Society review (www.ons.org)
- safety review (PMID 37110319)
Scalp cooling — 5 linked sources
Read the interpretation and limitations →
Evidence basis: SCALP randomized trial
- 2017 SCALP trial (jamanetwork.com)
- 2024 randomized trial (ascopubs.org)
- 2024 systematic review (PMID 38936283)
- safety review published November 21, 2025 (link.springer.com)
- 2021 ESMO dermatologic-toxicity guideline (www.annalsofoncology.org)
St. John’s wort and irinotecan — 2 linked sources
Read the interpretation and limitations →
Evidence basis: Small randomized crossover pharmacokinetic study
- Mathijssen et al., 2002 interaction study (PMID 12189228)
- NCI: Cancer therapy interactions (www.cancer.gov)
Strength training with lymphedema — 5 linked sources
Read the interpretation and limitations →
Evidence basis: Randomized trial, 141 participants
- 2009 randomized trial (PMID 19675330)
- systematic review in the 2019 journal collection (PMID 31406873)
- 2020 Oncology Nursing Society guideline (www.ons.org)
- NCI’s professional summary (www.cancer.gov)
- NCI advises calling promptly for fever or signs of cellulitis (www.cancer.gov)
Structured exercise after colon cancer — 2 linked sources
Read the interpretation and limitations →
Evidence basis: CHALLENGE randomized trial, 889 participants
- 2025 CHALLENGE randomized trial (PMID 40450658)
- ASCO’s exercise guideline (PMID 35576506)
Tai chi and qigong for fatigue — 1 linked sources
Read the interpretation and limitations →
Evidence basis: ASCO–SIO fatigue guideline, 2024
- ASCO–SIO fatigue guideline, 2024 (ascopubs.org)
Tart cherry for AI joint pain — 1 linked sources
Read the interpretation and limitations →
Evidence basis: Double-blind trial; 48 analyzed over six weeks
Vitamin B6 for hand–foot syndrome — 4 linked sources
Read the interpretation and limitations →
Evidence basis: Placebo-controlled phase III trial and other trials
- double-blind phase 3 trial (jamanetwork.com)
- meta-analysis (PMID 33190278)
- ESMO dermatologic-toxicity guideline (www.annalsofoncology.org)
- NIH Office of Dietary Supplements (ods.od.nih.gov)
Vitamin D for AI joint pain — 3 linked sources
Read the interpretation and limitations →
Evidence basis: Randomized trials
- 2019 randomized trial (PMID 31218477)
- 2017 VITAL trial in women starting letrozole (PMID 28770449)
- NIH vitamin D fact sheet (ods.od.nih.gov)
Yoga after treatment — 4 linked sources
Read the interpretation and limitations →
Evidence basis: YOCAS randomized trial
- multicenter randomized trial (pmc.ncbi.nlm.nih.gov)
- 2024 meta-analysis of 18 breast-cancer trials (PMID 38181269)
- 2024 ASCO–Society for Integrative Oncology guideline (ascopubs.org)
- NCCIH describes yoga as generally safe (www.nccih.nih.gov)
Zinc for taste changes — 4 linked sources
Read the interpretation and limitations →
Evidence basis: Phase III placebo-controlled trial
- multicenter N01C4 trial (PMID 17394940)
- 18-patient randomized trial (PMID 9587128)
- ESMO supportive-care guideline (doi.org)
- NIH Office of Dietary Supplements (ods.od.nih.gov)
← Return to Evidence Explorer · How to judge a study
October 13, 2026 additions and strengthened sources
Coenzyme Q10 for cancer-related fatigue — 5 linked sources
- Fatigue-focused randomized double-blind trial (PMID 22682875; NCT00096356)
- ClinicalTrials.gov posted results
- 2026 open-label paclitaxel trial (PMID 42401951)
- 2022 mixed-population fatigue meta-analysis (PMID 36091835)
- NCCIH CoQ10 safety overview
Clinical hypnosis for hot flashes after breast cancer — 3 linked sources
- 2008 breast-cancer survivor randomized trial (PMID 18809612)
- 2025 sham-controlled randomized trial (DOI 10.1001/jamanetworkopen.2025.42537)
- 2023 Menopause Society position statement (PMID 37252752)
Creatine for cancer-related wasting — 4 linked sources
- Alliance N02C4 randomized trial (PMID 28475678)
- 2026 systematic review and meta-analysis (DOI 10.1002/rco2.70044)
- ASCO cachexia guideline
- NIH ODS supplement fact sheet
Topical diclofenac for capecitabine hand–foot syndrome — 4 linked sources
- D-TORCH phase III trial (PMID 38412399)
- DICLO-HFS prospective real-world study (PMID 42623594)
- J-DIRECT randomized-trial protocol (PMID 40369354; protocol only)
- DailyMed diclofenac topical labeling
Acupuncture for aromatase-inhibitor joint pain — added trial and safety sources
- SWOG S1200 six-week randomized trial (PMID 29998338)
- SWOG S1200 52-week follow-up (PMID 36367721)
- NCCIH acupuncture safety overview
The 17 newly added external URLs are deduplicated in the updated count. Source links are not counts of independent clinical trials.
Sources added October 14, 2026
MS-N018 — dietary counseling
MS-N019 — neutropenic diets
MS-N020 — soy foods
MS-N021 — immunonutrition
MS-N022 — high-dose vitamin D
MS-N023 — high-vegetable diet
MS-N024 — selenium
MS-N025 — photobiomodulation
MS-N026 — self-acupressure
MS-N027 — pomegranate
Thirty newly indexed external URLs were deduplicated before the collection total was updated. Multiple publications from one study are not counted as independent trials.
Sources added October 15, 2026
MS-N029 — black cohosh
MS-N030 — guarana
MS-N031 — chamomile mouthwash
MS-N032 — calendula
MS-N033 — aloe vera
MS-N034 — vitamin E
MS-N035 — intravenous glutathione
MS-N036 — oral L-glutamine
MS-N037 — milk thistle
MS-N038 — Goshajinkigan
These ten records cite 39 external URLs. Thirty-seven were new to the repository; two were already indexed for other clinical questions. Multiple reports from one study are not counted as independent trials.
Sources added October 16, 2026
MS-N039 — postoperative shoulder rehabilitation
MS-N040 — head-and-neck exercise prehabilitation
MS-N041 — neoadjuvant breast exercise
MS-N042 — exercise with bone metastases
MS-N043 — ACTIVATE cognition trial
MS-N044 — ovarian neuropathy exercise
MS-N045 — manual lymph drainage
MS-N046 — swallowing exercises
MS-N047 — exercise during allogeneic transplant
MS-N048 — exercise for insomnia
These ten records cite 28 external URLs. All 28 were new to the repository’s URL index. Multiple publications or follow-up reports from one trial are not counted as independent trials.
Sources added October 17, 2026
Thirty-seven new source URLs were added for MS-N049–MS-N058. Two guideline URLs used in today’s appraisals were already indexed and were not counted twice.
- MELODY trial (PMID 41494146)
- MELODY full text (PMCID PMC12879169)
- MELODY registry (NCT05215353)
- MELODY DOI
- CHOICE trial (PMID 31081899)
- CHOICE full text (PMCID PMC6910189)
- CHOICE registry (NCT02356575)
- Tai Chi Chih insomnia trial (PMID 28489508)
- Tai Chi Chih insomnia full text (PMCID PMC5549450)
- Tai Chi Chih trial erratum (PMID 29244979)
- Tai Chi Chih inflammatory-marker follow-up (PMID 38777285)
- Bright-light chemotherapy pilot (PMID 21660669)
- Bright-light pilot full text (PMCID PMC3192914)
- Bright-light registry (NCT00478257)
- Bright-light survivor sleep trial (PMID 29198295)
- Bright-light survivor trial full text (PMCID PMC5734890)
- Expressive-writing RCC trial (PMID 24470003)
- Expressive-writing full text (PMCID PMC3927735)
- Expressive-writing registry (NCT00505310)
- Mindfulness fatigue meta-analysis (PMCID PMC12515675)
- Mindfulness fatigue review DOI
- Mindfulness fatigue pilot (PMCID PMC4331267)
- ONS mindfulness fatigue resource
- Yoga during radiotherapy trial (PMID 24590636)
- Yoga radiotherapy full text (PMCID PMC3965260)
- Later small yoga trial (PMID 36176568)
- Relaxation plus imagery trial full text (PMCID PMC4545275)
- Relaxation plus imagery trial (PMID 26347018)
- Relaxation plus imagery registry (NCT01275872)
- Relaxation plus imagery systematic review (PMID 29506956)
- Dignity-therapy trial (PMID 21741309)
- Dignity-therapy full text (PMCID PMC3185066)
- Dignity-therapy systematic review (PMCID PMC9941428)
- Meaning-centered group trial (PMID 25646186)
- Meaning-centered group trial full text (PMCID PMC4334778)
- Individual meaning-centered trial (PMID 29757459)
- Individual meaning-centered trial full text (PMCID PMC6097940)
Source links are not equivalent to independent trials. Trial reports, follow-up analyses, reviews, guidance and registry records are labeled separately.
Records added October 18, 2026
Acupuncture for cancer-related fatigue — 5 linked sources
Read the interpretation and limitations →
Evidence basis: Pragmatic randomized trial, sham-controlled trial context, systematic review and guidance
- Pragmatic randomized trial (PMID 23109700)
- DOI 10.1200/JCO.2012.41.6222
- Systematic review (PMCID PMC7533944)
- ASCO–SIO fatigue guideline
- NCI PDQ acupuncture summary
Acupuncture for chemotherapy neuropathy — 5 linked sources
Read the interpretation and limitations →
Evidence basis: Two small randomized trials, including a negative 2026 primary endpoint
- 2020 randomized pilot (PMID 32159808)
- 2020 full text (PMCID PMC7066475)
- 2026 randomized trial (PMID 42527066)
- DOI 10.21873/anticanres.18331
- NCCIH acupuncture safety
Acupuncture for chronic radiation xerostomia — 4 linked sources
Read the interpretation and limitations →
Evidence basis: 258-person multicenter randomized trial and registry
- 2024 randomized trial (PMID 38739392)
- Full text (PMCID PMC11091764)
- NCT02589938
- DOI 10.1001/jamanetworkopen.2024.10421
Acupuncture for chronic musculoskeletal pain — 4 linked sources
Read the interpretation and limitations →
Evidence basis: PEACE pragmatic randomized trial and registry
- PEACE trial (PMID 33734288)
- Full text (PMCID PMC7974834)
- NCT02979574
- DOI 10.1001/jamaoncol.2021.0310
Electroacupuncture for hot flashes — 4 linked sources
Read the interpretation and limitations →
Evidence basis: Four-arm randomized phase II trial and registry
- Randomized phase II trial (PMID 26304905)
- Full text (PMCID PMC4622101)
- NCT01005108
- DOI 10.1200/JCO.2015.60.9412
P6 acupressure wristbands for chemotherapy nausea — 4 linked sources
Read the interpretation and limitations →
Evidence basis: 500-person randomized trial, HTA report and meta-analysis
- ANCHoR trial (PMID 23803562)
- ANCHoR full text (PMCID PMC4781256)
- NIHR HTA report
- Meta-analysis (PMID 28231440)
Foot reflexology for advanced breast-cancer symptoms — 3 linked sources
Read the interpretation and limitations →
Evidence basis: Multicenter randomized trial and two reviews; full-text extraction incomplete
- Randomized trial (PMID 23107851)
- Systematic review (PMID 31783340)
- Review (PMID 28743659)
Oral cryotherapy for chemotherapy mucositis — 5 linked sources
Read the interpretation and limitations →
Evidence basis: Randomized trials, MASCC/ISOO guideline and Cochrane review
- Bolus 5-fluorouracil trial (PMID 1999715)
- DOI 10.1200/JCO.1991.9.3.449
- MASCC/ISOO guideline (PMID 31836937)
- Cochrane review (PMID 27583808)
- High-dose melphalan trial (PMID 33084773)
Scalp cooling for chemotherapy hair loss — 5 linked sources
Read the interpretation and limitations →
Evidence basis: SCALP randomized trial, registry, safety meta-analysis and regimen review
- SCALP trial (PMID 28196254)
- DOI 10.1001/jama.2016.20939
- NCT01986140
- Safety meta-analysis (PMID 41269388)
- Regimen effectiveness review (PMID 38936283)
Frozen gloves and socks for taxane neuropathy — 4 linked sources
Read the interpretation and limitations →
Evidence basis: CryoPac randomized trial, registry and prior review
- CryoPac trial (PMID 42838271)
- DOI 10.1016/j.annonc.2026.09.014
- NCT05928429
- Prior systematic review (PMID 38955817)
Sources added October 19, 2026
27 new external URLs were added after URL-level deduplication; one already-indexed ASCO cannabis guideline was reused. Multiple reports from the same trial are not counted as independent trials.
- MS-N069: curcumin–tamoxifen crossover pharmacokinetic study (PMID 30909366).
- MS-N070: DELCaP/SWOG S0221 ancillary cohort; MARIE cohort; 2021 systematic review/meta-analysis.
- MS-N071: one randomized trial, reported in second-primary/recurrence, mortality, and toxicity/recurrence papers.
- MS-N072: melanoma cohort plus mouse experiments; 2025 pooled atezolizumab analysis; 2024 prospective real-world cohort; 2026 meta-analysis.
- MS-N073: 2020 prospective cohort; 2025 CCTG pooled analysis; 2025 systematic review; reused ASCO cannabis guideline.
- MS-N074: etoposide crossover pilot; NCI PDQ interaction summary; nilotinib; sunitinib.
- MS-N075–N076: NCI PDQ reviews for Essiac/Flor Essence and Gerson therapy.
- MS-N077: review; case series; FDA warning letter; FDA health-fraud discussion.
- MS-N078: FDA consumer warning; FDA/DOJ case summary.
- Safety surveillance: FDA toxic-yellow-oleander alert, updated September 17, 2026.
